How much is the cardiac tissue engineering market worth, and how is it expected to expand?
The cardiac tissue engineering market size has grown rapidly in recent years. It will grow from $0.67 billion in 2024 to $0.81 billion in 2025 at a compound annual growth rate (CAGR) of 19.7%. The growth in the historic period can be attributed to organ donor shortages, increasing prevalence of cardiovascular diseases, innovations in biomaterials, rising investment in regenerative medicine, demand for personalized medicine, advancements in bioreactor systems, increasing government funding for biomedical research, and growing focus on minimally invasive therapies.
The cardiac tissue engineering market size is expected to see rapid growth in the next few years. It will grow to $1.64 billion in 2029 at a compound annual growth rate (CAGR) of 19.4%. The growth in the forecast period can be attributed to increasing demand for personalized cardiac therapies, rising focus on bioengineered heart tissues, expansion of regenerative medicine applications, increasing collaborations between biotech firms and academia, growing investment in preclinical testing platforms, and rising prevalence of chronic heart diseases. Major trends in the forecast period include the integration of AI in tissue engineering, advancements in nanotechnology-based scaffolds, the development of biodegradable hydrogels, progress in 3D bioprinting precision, the use of bioreactors for tissue maturation, and gene editing for cardiac cell enhancement.
Get Your Free Sample of The Global Cardiac Tissue Engineering Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21129&type=smp
Which industry factors have accelerated the cardiac tissue engineering market’s expansion?
The rising incidence of cardiovascular diseases is expected to propel the growth of the cardiac tissue engineering market going forward. Cardiac tissue engineering is the interdisciplinary field focused on creating biological or bioartificial constructs to repair, regenerate, or replace damaged heart tissue. The rising incidence of cardiovascular diseases is primarily driven by unhealthy lifestyle choices, including poor diet, physical inactivity, smoking, and increasing rates of obesity and diabetes. Cardiac tissue engineering is used in cardiovascular diseases by developing biomaterials, cell-based therapies, and bioengineered tissues to repair or regenerate damaged heart muscle and restore cardiac function. For instance, in May 2023, according to the Centers for Disease Control and Prevention, a US-based governmental organization, the percentage of coronary heart disease in female adults aged 18 and over slightly increased to 3.7% in 2023 from 3.6% in 2022. Therefore, the rising incidence of cardiovascular diseases is driving the growth of the cardiac tissue engineering market.
What are the primary segments of the cardiac tissue engineering market?
The cardiac tissue engineering market covered in this report is segmented –
1) By Product: Heart Valves, Vascular Grafts
2) By Material: Stem Cells, Scaffolds
3) By Application: Myocardial Infarction, Heart Valve Repair Or Replacement, Congenital Heart Disease Treatment, Other Applications
4) By End Users: Hospitals And Clinics, Academic And Research Institutes, Other End Users
Subsegments:
1) By Heart Valves: Bioprosthetic Heart Valves, Mechanical Heart Valves, Tissue-Engineered Heart Valves
2) By Vascular Grafts: Synthetic Vascular Grafts, Biologic Vascular Grafts, Tissue-Engineered Vascular Grafts
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/cardiac-tissue-engineering-global-market-report
Which firms are leading the cardiac tissue engineering market?
Major companies operating in the cardiac tissue engineering market are Biotronik SE & Co. KG, Terumo Corporation, Artivion Inc., Tissue Regenix Group plc, PromoCell GmbH, Xeltis AG, Carmat S.A., Bioheart Inc., Prellis Biologics Inc., Cytograft Tissue Engineering Inc., Avery Therapeutics Inc., Vascudyne Inc., Auto Tissue Berlin GmbH, CorMatrix Cardiovascular Inc., Humacyte Inc., BioCardia Inc., Osiris Therapeutics Inc., StemCells Inc., ViroMed Co. Ltd., Cardio3 Biosciences
Which market trends are set to define the future of the cardiac tissue engineering market?
Major companies operating in the cardiac tissue engineering market are focused on developing technological advancements, such as 3D-engineered muscle tissues, to enhance the accuracy and efficiency of drug discovery for effective treatments for cardiovascular diseases. 3D-engineered muscle tissues are bioengineered constructs that replicate the structural and functional properties of human muscle, typically used for drug testing and disease modeling. For instance, in July 2022, Curi Bio Inc., a US-based biotechnology company, launched the Mantarray platform for human-relevant 3D heart and skeletal engineered muscle tissue (EMT) contractility analysis. The platform uses advanced tissue culture techniques to create highly functional muscle tissues that replicate the mechanical properties and behavior of natural muscle, offering a more accurate model for testing drugs. This technology is designed to enhance the development of therapeutic solutions by allowing researchers to study muscle contraction, response to stimuli, and disease modeling at a cellular level.
Which geographic trends are shaping the cardiac tissue engineering market, and which region has the highest market share?
North America was the largest region in the cardiac tissue engineering market in 2024. The regions covered in the cardiac tissue engineering market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Cardiac Tissue Engineering Market Report 2025 Offer?
The cardiac tissue engineering market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Cardiac tissue engineering refers to the use of advanced biomedical techniques to develop functional heart tissue that can repair or regenerate damaged heart muscles. It involves combining cells, biomaterials, and bioactive factors to create engineered tissues that can restore cardiac function or aid in heart disease treatment.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21129
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
